These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

971 related articles for article (PubMed ID: 27039186)

  • 21. Trans-arterial radioembolization in intermediate-advanced hepatocellular carcinoma: systematic review and meta-analyses.
    Rognoni C; Ciani O; Sommariva S; Facciorusso A; Tarricone R; Bhoori S; Mazzaferro V
    Oncotarget; 2016 Nov; 7(44):72343-72355. PubMed ID: 27579537
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Safety and Efficacy of Liver Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma After Segmental Transarterial Radioembolization.
    Hardy-Abeloos C; Lazarev S; Ru M; Kim E; Fischman A; Moshier E; Rosenzweig K; Buckstein M
    Int J Radiat Oncol Biol Phys; 2019 Dec; 105(5):968-976. PubMed ID: 31536781
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Transarterial therapies in patients with hepatocellular carcinoma eligible for transarterial embolization: a US cost-effectiveness analysis.
    Patel MV; Davies H; Williams AO; Bromilow T; Baker H; Mealing S; Holmes H; Anderson N; Ahmed O
    J Med Econ; 2023; 26(1):1061-1071. PubMed ID: 37632520
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Yttrium-90 radioembolization vs sorafenib for intermediate-locally advanced hepatocellular carcinoma: a cohort study with propensity score analysis.
    Gramenzi A; Golfieri R; Mosconi C; Cappelli A; Granito A; Cucchetti A; Marinelli S; Pettinato C; Erroi V; Fiumana S; Bolondi L; Bernardi M; Trevisani F;
    Liver Int; 2015 Mar; 35(3):1036-47. PubMed ID: 24750853
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The position of transarterial chemoembolization with drug-eluting beads and yttrium-90 transarterial radioembolization in patients with hepatocellular carcinoma: Consensus statements from a Delphi-method expert panel in Turkey.
    Akarca US; Akhan O; Bilgiç S; Bozkurt MF; Cantaşdemir M; Çermik TF; Çakaloğlu Y; Er Ö; Ilgıt E; Çapa Kaya G; Küçük NÖ; Numan F; Parıldar M; Türkmen C
    Diagn Interv Radiol; 2021 Nov; 27(6):732-739. PubMed ID: 34792027
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Transarterial radioembolization with yttrium-90 of unresectable primary hepatic malignancy in children.
    Aguado A; Ristagno R; Towbin AJ; Gupta A; Haberle S; Qi Z; Patel MN; Kukreja KU; Tiao GM; Geller JI
    Pediatr Blood Cancer; 2019 Jul; 66(7):e27510. PubMed ID: 30406959
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Safety and Efficacy of Transarterial Radioembolisation in Patients with Intermediate or Advanced Stage Hepatocellular Carcinoma Refractory to Chemoembolisation.
    Klompenhouwer EG; Dresen RC; Verslype C; Laenen A; De Hertogh G; Deroose CM; Bonne L; Vandevaveye V; Maleux G
    Cardiovasc Intervent Radiol; 2017 Dec; 40(12):1882-1890. PubMed ID: 28685382
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Transarterial radioembolization in patients with hepatocellular carcinoma of intermediate B2 substage.
    Cappelli A; Sangro P; Mosconi C; Deppe I; Terzi E; Bilbao JI; Rodriguez-Fraile M; De Benedittis C; Ricke J; Golfieri R; Sangro B
    Eur J Nucl Med Mol Imaging; 2019 Mar; 46(3):661-668. PubMed ID: 30209522
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Feasibility and safety of liver transplantation or resection after transarterial radioembolization with Yttrium-90 for unresectable hepatocellular carcinoma.
    Labgaa I; Tabrizian P; Titano J; Kim E; Thung SN; Florman S; Schwartz M; Melloul E
    HPB (Oxford); 2019 Nov; 21(11):1497-1504. PubMed ID: 31005494
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Resin Versus Glass Microspheres for
    Van Der Gucht A; Jreige M; Denys A; Blanc-Durand P; Boubaker A; Pomoni A; Mitsakis P; Silva-Monteiro M; Gnesin S; Lalonde MN; Duran R; Prior JO; Schaefer N
    J Nucl Med; 2017 Aug; 58(8):1334-1340. PubMed ID: 28082436
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Treatment for hepatocellular carcinoma with portal vein tumor thrombosis: the emerging role for radioembolization using yttrium-90.
    Lau WY; Sangro B; Chen PJ; Cheng SQ; Chow P; Lee RC; Leung T; Han KH; Poon RT
    Oncology; 2013; 84(5):311-8. PubMed ID: 23615394
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Y90 Radioembolization Dosimetry: Concepts for the Interventional Radiologist.
    Toskich BB; Liu DM
    Tech Vasc Interv Radiol; 2019 Jun; 22(2):100-111. PubMed ID: 31079706
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Favorable survival time provided with radioembolization in hepatocellular carcinoma patients with and without portal vein thrombosis.
    Ozkan ZG; Poyanli A; Ucar A; Kuyumcu S; Akyuz F; Keskin S; Saglam S; Yilmaz E; Karaca C; Turkmen C
    Cancer Biother Radiopharm; 2015 Apr; 30(3):132-8. PubMed ID: 25760644
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Transarterial Radioembolization Versus Atezolizumab-Bevacizumab in Unresectable Hepatocellular Carcinoma: A Matching-Adjusted Indirect Comparison of Time to Deterioration in Quality of Life.
    Agirrezabal I; Brennan VK; Colaone F; Shergill S; Pereira H; Chatellier G; Vilgrain V
    Adv Ther; 2022 May; 39(5):2035-2051. PubMed ID: 35279814
    [TBL] [Abstract][Full Text] [Related]  

  • 35.
    Dhondt E; Lambert B; Hermie L; Huyck L; Vanlangenhove P; Geerts A; Verhelst X; Aerts M; Vanlander A; Berrevoet F; Troisi RI; Van Vlierberghe H; Defreyne L
    Radiology; 2022 Jun; 303(3):699-710. PubMed ID: 35258371
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Open-label prospective study of the safety and efficacy of glass-based yttrium 90 radioembolization for infiltrative hepatocellular carcinoma with portal vein thrombosis.
    Kokabi N; Camacho JC; Xing M; El-Rayes BF; Spivey JR; Knechtle SJ; Kim HS
    Cancer; 2015 Jul; 121(13):2164-74. PubMed ID: 25847227
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Disease control and failure patterns of unresectable hepatocellular carcinoma following transarterial radioembolization with yttrium-90 microspheres and with/without sorafenib.
    Teyateeti A; Mahvash A; Long J; Abdelsalam M; Avritscher R; Kaseb A; Odisio B; Ravizzini G; Surasi D; Teyateeti A; Macapinlac H; Kappadath SC
    World J Gastroenterol; 2021 Dec; 27(47):8166-8181. PubMed ID: 35068861
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Association Between Curative Treatment after Transarterial Radioembolization and Better Survival Outcomes in Patients with Hepatocellular Carcinoma.
    Kim Y; Lee HA; Lee JS; Jeon MY; Kim BK; Park JY; Kim DY; Ahn SH; Um SH; Seo YS; Kim SU
    Cancer Invest; 2021 Mar; 39(3):274-283. PubMed ID: 33356630
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Boosted-Dose Yttrium-90 Radiation Segmentectomy or Lobectomy for Hepatocellular Carcinoma Refractory to Prior Transarterial Embolization or Chemoembolization: A Single Institution Retrospective Case Series.
    Srinivas S; Rose SC; Al Jammal O; Hsieh LJ; Rockwell HD; Duncan DP; Minocha J; Berman ZT
    Cardiovasc Intervent Radiol; 2023 Apr; 46(4):460-469. PubMed ID: 36854903
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Radioembolization results in longer time-to-progression and reduced toxicity compared with chemoembolization in patients with hepatocellular carcinoma.
    Salem R; Lewandowski RJ; Kulik L; Wang E; Riaz A; Ryu RK; Sato KT; Gupta R; Nikolaidis P; Miller FH; Yaghmai V; Ibrahim SM; Senthilnathan S; Baker T; Gates VL; Atassi B; Newman S; Memon K; Chen R; Vogelzang RL; Nemcek AA; Resnick SA; Chrisman HB; Carr J; Omary RA; Abecassis M; Benson AB; Mulcahy MF
    Gastroenterology; 2011 Feb; 140(2):497-507.e2. PubMed ID: 21044630
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 49.